-
公开(公告)号:US20230030968A1
公开(公告)日:2023-02-02
申请号:US17878258
申请日:2022-08-01
发明人: Jeffrey D. Rimer , Xi Geng , Ricardo Sosa
IPC分类号: C02F5/10
摘要: Analogues of citrate, namely hydroxycitrate (HCA) and isocitrate (ICA), have dual roles as nucleation inhibitors and growth suppressors in the formation of mineral scale. Their potency is comparable to commercial phosphorous-based inhibitors, but they are more environmentally friendly, which has practical advantages for use in a broad range of commercial applications.
-
公开(公告)号:US11866325B2
公开(公告)日:2024-01-09
申请号:US17054861
申请日:2019-05-15
发明人: Jeffrey D. Rimer , Manjesh Kumar
IPC分类号: C01B39/26
CPC分类号: C01B39/265 , C01P2002/01 , C01P2002/72 , C01P2002/85 , C01P2004/04 , C01P2004/24 , C01P2004/64
摘要: The methods for synthesizing mordenite (MOR) zeolite crystals described herein utilize a combination of organics and produce MOR crystals with reduced size, higher Si/Al ratio, fewer stacking faults, less occluded organics in the final product, and a longer catalyst lifetime.
-
公开(公告)号:US20230077288A1
公开(公告)日:2023-03-09
申请号:US17798748
申请日:2021-02-09
发明人: Jeffrey D. Rimer , Yufeng Shen , Heng Dai
摘要: A secondary growth procedure described herein is used to prepare finned zeolites. The finned zeolites possess properties that are distinctly unique compared to crystals of similar size lacking fins. The procedure is amenable to a wide range of zeolite crystal structures.
-
4.
公开(公告)号:US20170247261A1
公开(公告)日:2017-08-31
申请号:US15511776
申请日:2015-09-17
IPC分类号: C01B39/46 , B01J37/00 , B01J29/70 , B01J39/02 , B01J37/04 , B01J37/10 , B01J39/14 , C01B39/20 , B01J29/08
CPC分类号: C01B39/46 , B01J29/08 , B01J29/084 , B01J29/085 , B01J29/70 , B01J29/7003 , B01J29/7049 , B01J37/0072 , B01J37/009 , B01J37/04 , B01J37/10 , B01J39/02 , B01J39/14 , C01B39/14 , C01B39/20 , C01B39/24 , C01P2004/32 , C01P2004/38 , C01P2004/61 , C01P2004/62
摘要: In an embodiment, the present disclosure pertains to a composition comprising a zeolite with high silica content. In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is 2:1. In some embodiments, the zeolite comprises Zeolite HOU-2 (LTA-type). In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is >3. In some embodiments, the zeolite comprises Zeolite HOU-3 (FAU type). In some embodiments, the zeolite is synthesized using a one-step method. In some embodiments, the zeolite is synthesized without the use of an organic structure-directing agent (OSDA). In some embodiments, the zeolite is synthesized without the use of post-synthesis dealumination. In some embodiments, the zeolite is synthesized without the use crystal seeds. In some embodiments, the zeolite is used in commercial ion exchange. In some embodiments, the zeolite is used for catalysis reaction. In some embodiments, the zeolite is highly thermostable.
-
公开(公告)号:US20230399234A1
公开(公告)日:2023-12-14
申请号:US18334678
申请日:2023-06-14
IPC分类号: C01B39/48
CPC分类号: C01B39/48 , C01P2004/64
摘要: Nano-sized zeolites may be prepared using germanium oxide (GeO2) as a component of the overall synthesis composition. This is accomplished by the addition of GeO2 as an inexpensive reagent for the synthesis gel. Most of the Ge is retained in the synthesis mixture and the small amount incorporated in the zeolite solid (Si/Ge>100) does not have an appreciable impact on zeolite acidity or other physicochemical properties. The methods disclosed herein circumvent challenges to prepare nano-sized zeolites having dimensions less than 100 nm.
-
6.
公开(公告)号:US10662070B2
公开(公告)日:2020-05-26
申请号:US16183862
申请日:2018-11-08
发明人: Jeffrey D. Rimer , Manjesh Kumar
IPC分类号: C01B39/04 , B01J29/70 , C01B39/48 , B01J29/85 , C01B39/54 , B01J47/00 , C30B7/14 , C30B29/14 , C30B29/34 , C30B29/60 , B01J29/06 , B01J35/00 , B01J35/02 , B01J29/035
摘要: Embodiments of the invention generally provide compositions of crystalline zeolite materials with tailored crystal habits and the methods for forming such crystalline zeolite materials. The methods for forming the crystalline zeolite materials include binding one or more zeolite growth modifiers (ZGMs) to the surface of a zeolite crystal, which results in the modification of crystal growth rates along different crystallographic directions, leading to the formation of zeolites having a tailored crystal habit. The improved properties enabled by the tailored crystal habit include a minimized crystal thickness, a shortened internal diffusion pathlength, and a greater step density as compared to a zeolite having the native crystal habit prepared by traditional processes. The tailored crystal habit provides the crystalline zeolite materials with an aspect ratio of about 4 or greater and crystal surfaces having a step density of about 25 steps/μm2 or greater.
-
公开(公告)号:US10407312B2
公开(公告)日:2019-09-10
申请号:US15511776
申请日:2015-09-17
IPC分类号: C01B39/14 , C01B39/20 , B01J29/08 , B01J29/70 , B01J37/10 , C01B39/46 , C01B39/24 , B01J37/00 , B01J37/04 , B01J39/02 , B01J39/14
摘要: In an embodiment, the present disclosure pertains to a composition comprising a zeolite with high silica content. In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is 2:1. In some embodiments, the zeolite comprises Zeolite HOU-2 (LTA-type). In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is >3. In some embodiments, the zeolite comprises Zeolite HOU-3 (FAU type). In some embodiments, the zeolite is synthesized using a one-step method. In some embodiments, the zeolite is synthesized without the use of an organic structure-directing agent (OSDA). In some embodiments, the zeolite is synthesized without the use of post-synthesis dealumination. In some embodiments, the zeolite is synthesized without the use crystal seeds. In some embodiments, the zeolite is used in commercial ion exchange. In some embodiments, the zeolite is used for catalysis reaction. In some embodiments, the zeolite is highly thermostable.
-
8.
公开(公告)号:US10173903B2
公开(公告)日:2019-01-08
申请号:US14305097
申请日:2014-06-16
发明人: Jeffrey D. Rimer , Manjesh Kumar
IPC分类号: C01B39/04 , C01B39/54 , B01J47/00 , C30B7/14 , C30B29/14 , C30B29/34 , B01J29/70 , B01J29/06 , B01J29/85 , B01J35/00 , B01J35/02 , B01J29/035
摘要: Embodiments of the invention generally provide compositions of crystalline zeolite materials with tailored crystal habits and the methods for forming such crystalline zeolite materials. The methods for forming the crystalline zeolite materials include binding one or more zeolite growth modifiers (ZGMs) to the surface of a zeolite crystal, which results in the modification of crystal growth rates along different crystallographic directions, leading to the formation of zeolites having a tailored crystal habit. The improved properties enabled by the tailored crystal habit include a minimized crystal thickness, a shortened internal diffusion pathlength, and a greater step density as compared to a zeolite having the native crystal habit prepared by traditional processes. The tailored crystal habit provides the crystalline zeolite materials with an aspect ratio of about 4 or greater and crystal surfaces having a step density of about 25 steps/μm2 or greater.
-
公开(公告)号:US20240173705A1
公开(公告)日:2024-05-30
申请号:US18277261
申请日:2022-02-16
发明人: Jeffrey D. Rimer , Rishabh Jain
CPC分类号: B01J29/40 , B01J35/40 , B01J37/031 , B01J37/08
摘要: Interconnected zeolite nanosheets with a structural motif resembling self-pillared pentasil zeolites are synthesized through the use of MEL or MFI-type zeolites as crystalline seeds. The use of MEL- or MFI-type zeolites as crystalline seeds induces the spontaneous formation of pillared zeolites, thus avoiding, for the first time, the use of any organic or branching template for the crystallization of these hierarchical structures.
-
公开(公告)号:US20200009163A1
公开(公告)日:2020-01-09
申请号:US16490959
申请日:2018-03-06
发明人: Jeffrey D. Rimer , Bryan G. Alamani
IPC分类号: A61K31/6615 , A61K33/42 , A61P13/04 , A61P3/14
摘要: Embodiments described herein generally relate to compositions and methods requiring these compositions that may act to reduce the incidence and/or reoccurrence of kidney stones and/or other pathological calcification diseases, symptoms, or conditions. The compositions include a polyphosphate material, which may be method of treating pathological calcification. In some embodiments, the polyphosphate material included in the composition to be administered may be a linear tripolyphosphate material or a hexametaphosp hate material.
-
-
-
-
-
-
-
-
-